**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 84673

**Manuscript Type:** REVIEW

**Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications**

Guo GJ *et al*. Gut microbiome and MAFLD

Gong-Jing Guo, Fei Yao, Wei-Peng Lu, Hao-Ming Xu

**Gong-Jing Guo,** Gastroenterology Department of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People’s Hospital of Shenzhen, Shenzhen 518172, Guangdong Province, China

**Fei Yao,** Department of Science and Education, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou 510370, Guangdong Province, China

**Wei-Peng Lu,** The First Clinical School, Guangzhou Medical University, Guangzhou 510120, Guangdong Province, China

**Hao-Ming Xu,** Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, Guangdong Province, China

**Author contributions:** GuoGJ and Yao F performed the majority of the draft writing, revision of manuscript and prepared the references; Lu WP prepared the figures and table, coordinated the writing of the paper; Xu HM organized the interpretation of the data and revision of the article.

**Supported by** Guangzhou Planned Project of Science and Technology, No. 2023A04J0612.

**Corresponding author: Hao-Ming Xu, Doctor, MD, Doctor,** Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, No. 1 Panfu Road, Guangzhou 510180, Guangdong Province, China. haomingxu1992@126.com

**Received:** March 23, 2023

**Revised:** June 11, 2023

**Accepted:** June 30, 2023

**Published online:**

**Abstract**

Metabolic-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases worldwide. In recent years, the occurrence rate of MAFLD has been on the rise, mainly due to lifestyle changes, high-calorie diets, and imbalanced dietary structures, thereby posing a threat to human health and creating heavy social and economic burdens. With the development of 16S sequencing and integrated multi-omics analysis, the role of the gut microbiota (GM) and its metabolites in MAFLD has been further recognized. The GM plays a role in digestion, energy metabolism, vitamin synthesis, the prevention of pathogenic bacteria colonisation, and immunoregulation. The gut-liver axis is one of the vital links between the GM and the liver. Toxic substances in the intestine can enter the liver through the portal vascular system when the intestinal barrier is severely damaged. The liver also influences the GM in various ways, such as bile acid circulation. The gut-liver axis is essential in maintaining the body’s normal physiological state and plays a role in the onset and prognosis of many diseases, including MAFLD. This article reviews the status of the GM and MAFLD and summarizes the GM characteristics in MAFLD. The relationship between the GM and MAFLD is discussed in terms of bile acid circulation, energy metabolism, micronutrients, and signalling pathways. Current MAFLD treatments targeting the GM are also listed.

**Key Words:** Metabolic-associated fatty liver disease; Gut microbiota; Current status; Application

Guo GJ, Yao F, Lu WP, Xu HM. Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications. *World J Hepatol* 2023; In press

**Core Tip:** Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent metabolic disease worldwide. In this review, we provide an overview of the current status and potential applications of the gut microbiota (GM) in MAFLD, focusing on key aspects such as bile acid circulation, energy metabolism, and microelement disorder, as well as signal pathways and GM metabolites implicated in MAFLD development and treatments, with a particular emphasis on targeting the microbiome.

**INTRODUCTION**

Metabolic-associated fatty liver disease (MAFLD), originally known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver diseases worldwide. Liver inflammation and fibrosis are the pathological processes implicated in MAFLD. MAFLD can develop into non-alcoholic steatohepatitis (NASH), which can then progress to liver cirrhosis, hepatic failure, and liver cancer[1]. The rate of MAFLD has been on the rise, with a global rate of 25%-30%, due to lifestyle changes, excessive calorie intake, and unbalanced diet structures. In certain groups, such as patients with Type 2 diabetes, the rate of MAFLD even exceeds 70%[2,3]. MAFLD poses a threat to human health and leads to substantial social and economic burdens. The gut microbiota (GM) lives in the human intestinal tract. In the past 10 years, there has been an exponential growth of studies on the relationship between GM and human health and disease in databases such as PubMed. The GM consists of over 1014 microorganisms[4], and its genome comprises of over 3 million genes, whereas  the human genome consists of approximately 23000 genes[5]. Therefore, the GM is considered as one of the “new organs” in human beings. Steady-state GM plays a role in digestion, energy metabolism, vitamin synthesis, the prevention of pathogenic bacteria colonisation, and immunoregulation[6,7]. The gut-liver axis is one of the vital links between the GM and the liver. The intestine and liver both originate from the ventral foregut endoderm. When the intestinal barrier is severely damaged, toxic substances in the intestinal tract enter the portal vein through the superior and inferior mesenteric veins and then flow into the liver. Meanwhile, the liver influences the intestinal microecology in various ways. For example, the liver secretes bile acids, which enter in the enterohepatic circulation to alter the intestinal microecology[8]. In recent years, the development of 16S sequencing and integrated multi-omics analysis has helped to further understand the role of the GM and its metabolites in MAFLD. It is reported that *Akkermansia muciniphila* can improve liver function, reduce oxidative stress, inhibit inflammation, and reverse the metabolic disorder caused by high-fat diets[9]. Some secondary bile acid-producing bacteria, such as *Lactobacillaceae* and *Lachnospiracea*, have cholesterol-reducing potential[10]. Specific bile acids produced by bacteria can regulate GM structure and restore GM balance[11]. Numerous studies have confirmed that GM metabolites play a significant role in the onset and progression of MAFLD when they are present in the intestine or enter the circulation. GM can mediate the fermentation of dietary fibres, leading to the production of short-chain fatty acids (SCFAs) as the primary metabolites of this process. Among the SCFAs, butyric acid can improve the MAFLD induced by high-fat diets *via* activating peroxisome proliferator-activated receptor α to inhibit liver inflammation and enhance the expression of glucagon-like peptide-1 receptor[12]. Furthermore, SCFAs can also activate G-protein-coupled receptor and induce the release of glucagon-like peptide-1 (GLP-1) and peptide YY, resulting in metabolically balanced feedback regulation[13]. SCFAs can not only regulate glycolipid metabolism, inhibit fat synthesis, and reduce liver fat content but also escalate intestinal barrier function, thereby improving MAFLD[14]. Therefore, the main aims of this research field are to observe and characterize the GM in MAFLD, investigate the impact of GM and its metabolites on the onset and progression of MAFLD, and explore the potential of targeting the GM for MAFLD treatment.

This article primary focuses on elucidating the impact of the gut-liver axis on MAFLD. It provides an overview of the existing clinical MAFLD cases and commonly utilized animal models. The review involves the important aspects such as bile acid circulation, energy metabolism, microelement disorder, and other relevant factors such as signal pathways and GM metabolites implicated the development of MAFLD. Then, current MAFLD treatments utilizing GM as the target are presented. Table 1 summarizes the key characteristics of GM in both clinical MAFLD cases and commonly used MAFLD animal models.

**GM AND METABOLIC DISORDERS IN MAFLD**

***Bile acid metabolism disorders***

Primary bile acids are synthesized in the liver before being secreted into the gall bladder and released into the duodenum after a meal. Bacteria metabolize primary bile acids in the intestinal tract into secondary bile acids, which are then reabsorbed into the portal vein. While most bile acid molecules are captured by the liver and undergo recirculation, a small fraction of them persists in the blood as signalling molecules. Bile acid synthesis in hepatocytes involves the oxidation of cholesterol mediated by cytochromes P450 enzymes. The synthesis mainly occurs through the classic and alternative pathways, producing cholic and chenodeoxycholic acids, which are subsequently conjugated to taurine and glycine, respectively, to form conjugated bile acids. Synthesized primary bile acids are deposited into the gallbladder *via* the bile salt export pump. Gall bladder contraction triggered by eating promotes bile acid secretion into the intestinal tract[15]. Primary bile acids increase the permeability of the intestinal mucosa, resulting in endotoxemia and aggravating MAFLD. Thus, the bile acid level is elevated in the liver tissue, serum, and urine of MAFLD patients. Meanwhile, there is a significantly higher proportion of hydrophobic and cytotoxic bile acids[16]. Patients with NASH exhibit increased synthesis of bile acids compared to other conditions. The ratio of primary bile acids to secondary bile acids is also higher than in healthy individuals[17]. Bile salt hydrolases produced by *Bacteroides*, *Clostridium*, *Lactobacillus*, *Bifidobacterium*, and *Listeria* in the GM can deconjugate conjugated bile acids to form free bile acids. *Clostridium*, *Fusobacterium*, *Peptococcus*, and *Pseudomonas* species have the ability to catalyze the desulfuration of bile acids. *Bacteroides*, *Eubacterium*, *Clostridium*, *Escherichia*, *Eggerthella*, *Peptostreptococcus*, and *Ruminococcus* are implicated in the dehydroxylation of primary bile acids to produce secondary bile acids[18]. Moreover, it was found that *Clostridium leptum* is positively related to taurocholic acid and negatively related to cholic acid and chenodeoxycholic acid. This indicates that *Clostridium leptum* may promote the transformation from primary bile acids to secondary bile acids, thereby reducing the damage caused by primary bile acids to the liver[19].

About 95% of primary and secondary bile acids can be reabsorbed in the intestine and transported back into the liver through the portal veins. However, lithocholic acids present in secondary bile acids are primarily excreted with the feces. Hepatocytes synthesize new bile acids to compensate for the bile acids lost in the enterohepatic circulation. After reabsorption, bile acids are conjugated to the farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (GPBAR; also named TGR5), thereby promoting the secretion of fibroblast growth factor 19 (FGF19) by intestinal cells. FGF19 conjugates to fibroblast growth factor receptor 4 (FGFR4), activating c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK). These two signaling pathways decrease the genetic expression of cholesterol 7 α-hydroxylase (CYP7A1), which inhibits bile acid synthesis through negative feedback[20]. The effect of choline on lipid metabolism may be mediated by activating FXR to participate in liver lipid metabolism, thereby reducing the synthesis of cholesterol and triglycerides. The effect of bile acids on glucose metabolism has been established, as evidenced by the presence of insulin resistance and hyperglycemia in FXR gene-deficient mice, and the administration of oral dietary cholic acid to activate FXR can inhibit the expression of the gluconeogenesis gene in mice, reduce fasting glucose, and increase insulin sensitivity. Choline alleviates metabolic inflammation induced by tumor necrosis factor-alpha (TNF-α) and lipopolysaccharides (LPS), while bile acids such as cholic acid, deoxycholic acid, and chenodeoxycholic acid can inhibit the release of monocyte chemotactic protein-1 induced by TNF and LPS, suggesting that bile acids have anti-inflammatory effects[21]. Choline is a pleiotropic hormone-like signaling molecule with both metabolic and endocrine functions. It plays an important role in regulating cholesterol and triglyceride metabolism, insulin resistance, metabolic inflammation, and liver steatosis *via* activation of choline-specific receptors that are widely distributed in the body.

GM can regulate the synthesis and reabsorption of bile acids. Germ-free animals exhibit reduced excretion of bile acids in feces, accompanied by a significant increase in the total bile acid content in the gall bladder and small intestine[22,23]. Probiotics supplements or fecal microbiota transplantation can distinctly reduce the total bile acid content in the liver, gall bladder, and cecum germ-free animals[24]. In aseptic conditions, tauro-β-muricholic acid, a primary bile acid, accumulates due to its inability to undergo further metabolism. It can be used as an antagonist to inhibit intestinal FXR expression, thereby downregulating FXR expression. The expression of liver CYP7A1 promotes liver bile acid synthesis and is regulated via the enterohepatic circulation[23]. There is an increased expression of bile acid transporters in the ileum and colon of germ-free animals. This leads to decreased bile acid excretion in the feces, resulting in highly efficient bile acid reabsorption. The key enzymes in bile acid synthesis, such as CYP7A1, CYP7B1, and CYP27A1, can all be regulated by the GM, mainly via induction of the FXR signaling pathway[25]. Moreover, bile acids also have ab effect on the GM. Amphipathic bile acids directly perform the anti-bacterial function by breaking the cell membrane of bacteria, which is critical to maintaining the steady state of the bacterial flora. Studies revealed that bile duct ligation could arouse bacterial translocation in rat’s mesenteric lymph nodes as early as after one week. Three weeks after bile duct ligation, the translocation was found to be expanded to tissue such as the liver, spleen, and lung. In addition, gram-negative bacteria in the animal cecum and endotoxin levels in the blood were significantly elevated. The villi of the distal ileum were flattened, and Peyer’s patches increased in size[26]. Bacteria overgrowth in the small intestine, bacterial translocation, and endotoxemia can be effectively inhibited by taking bile acids orally[27]. Secondary bile acids can inhibit the growth of *Clostridium difficile*[28]. In addition, bile acids can enrich the bacteria that utilize bile acids. For example, bacteria with bile salt hydrolase activity, such as *Lactobacillus reuteri*, can resist cytotoxicity resulting from bile salts[29]. An in vitro culture experiment revealed that bile acids were required for the growth of *Bilophila wadsworthia*[30]. Studies have shown that diets rich in milk fat altered the bile acid profile, mainly by increasing the total amount of bile acid, and the abundance of *Bilophila wadsworthia* also increased with the increase in bile acids.

***Choline metabolism disorders***

Choline is a quaternary amine rich in methyl groups that exists in tissues in either free or esterified forms. In the liver, choline exists in the form of phosphatidylcholine (PC). Choline has been recognized as an essential nutrient by the National Academy of Sciences (NAS) since 1998. The biological functions of choline mainly include neurotransmitter synthesis, lipid metabolism, and cell membrane signal transduction. Choline can also serve as a methyl donor for the synthesis of PC in the liver[31]. PC, in turn, is indispensable for the synthesis and secretion of very low-density lipoprotein (VLDL). Moreover, choline also prevents abnormal lipid accumulation by mediating liver lipid transport. Therefore, the lack of choline may lead to hepatic steatosis[32]. For over 50 years, researchers have recognized the association between choline deficiency and accumulation of fat in the liver. Choline-deficient diets are often used in animal experiments to induce MAFLD. The administration of diets deficient in choline and vitamin B12 to weanling rats induces fatty liver and renal cortical necrosis, resulting in high deaths rate within 10 d[33,34]. Research has demonstrated that patients with MAFLD exhibit varying degrees of decreased choline levels in their plasma, which is associated with the degree of liver damage[31,35].

Choline has two primary sources. Approximately 70% of choline is obtained from dietary sources, while the remaining 30% is synthesized by the GM. Among 79 gut microbiota strains screened from the human gastrointestinal tract, eight strains have been identified to significantly affect choline metabolism (*Anaerococcus hydrogenalis*, *Clostridium asparagiforme*, *Clostridium hathewayi*, *Clostridium sporogenes*, *Edwardsiella tarda*, *Escherichia fergusonii*, *Proteus penneri*, and *Providencia rettgeri*). However, genetic analysis has revealed that the gene set responsible for anaerobic choline metabolism is widely distributed among the three main bacterial groups present in the human gut, including *Proteobacteria*, *Firmicutes*, and *Actinobacteria*. This metabolic pathway contributes to the bioavailability of choline in the human body and subsequently affects serum choline concentration. On the other hand, choline levels in the diet may also affect the gut microbiota. In patients with choline deficiency, choline supplementation has been shown to decrease the abundance of *Gammaproteobacteria*. This reduction in *Gammaproteobacteria* can alleviate the inhibition of key enzymes in choline metabolism, thereby reducing the occurrence of MAFLD[36-38]. As a result, GM disruption can alter choline metabolism and reduce the host’s capacity to efficiently utilize choline, leading to a relative deficiency of choline and increased production of substances such as trimethylamine N-oxide (TMAO). In turn, this can lead to the occurrence of hepatic steatosis[32,39,40]. Bacterial species such as *Escherichia coli* and *Desulfovibrio desulfuricans* within in GM have the capability to utilize choline and convert it into methylamine. When there is a disruption in the GM involved in the metabolism of choline, it can lead to a deficiency of choline and potentially contribute to the development of MAFLD[40]. In the presence of abundant MAFLD-associated intestinal bacteria, there is an increase demand for choline by these bacteria. This leads to choline deficiency in the host, exacerbating the risk of MAFLD and potentially progressing to NASH[41]. Reduced choline utilization may lead to decreased PC synthesis in the body, thereby inducing fatty acid synthesis and increasing triglyceride (TG) production. Meanwhile, it decreases the surface activity of lipid droplets lacking PC. Large lipid droplets are easier to form. Therefore, it is difficult for lipoprotein lipase (LPL) to decompose lipid droplets[9,42]. GM disruption can alter the body’s reservoir of choline, thereby inducing choline deficiency and decreasing VLDL secretion, which leads to the accumulation of fat in the liver[43]. Moreover, TMAO and GM are closely associated with choline metabolism. GM can produce enzymes that catalyze the transformation of dietary choline into methylamine. After metabolism, methylamine is transformed into TMAO by GM-produced trimethylamine-lyase. TMAO can regulate protein activity and stability, increase foam cell production, inhibit cholesterol transport, aggravate liver fat deposition, and even induce liver inflammation[31,32,44]. Trimethylamine lyases in GM can decompose dietary choline into TMA, which enters the liver through the portal vein and is oxidated into TMAO. TMAO can upregulate the expression of sterol regulatory element-binding protein-1c (SREBP-1c). SREBP-1c is a critical transcription factor in the regulation of liver lipid metabolism, which promotes TG synthesis, aggravating hepatic steatosis[45]. TMAO also upregulates glucose metabolism and increases serum inflammatory factors for insulin resistance (IR) promotion[46,47]. It affects lipid metabolism and cholesterol’s steady state by reducing the transformation of cholesterols into bile acids[35]. TMAO contributes to the progression of MAFLD through various mechanisms. GM metabolites also include secondary bile acids and ethanol, which have been discussed in the previous section.

***Lipid metabolism disorders***

The GM has the ability to generate energy from indigestible substances (*e.g.*, *Firmicutes* can ferment resistant starch to provide energy for intestinal epithelial cells)[48]. Therefore, GM is critical in the development of obesity, and it disruption can lead to obesity-related MAFLD[49]. Obesity can increase the level of proinflammatory cytokines secreted by macrophages and promote adipose tissue infiltration, leading to the development of hepatic steatosis[50]. The intestines of obese people are rich in *Firmicutes*. *Firmicutes* can ferment indigestible dietary fiber (polysaccharide) and produce additional energy from the intestine content, which promotes the progression of obesity and MAFLD. The fecal microbiota of obese mice caused by high-fat fodder was transplanted to mice fed with regular fodder, and it was found that mice transplanted with fecal microbiota on a high-fat diet had more fat deposition than mice transplanted with fecal microbiota on a regular diet. A further study found that structural changes in the GM could lead to greater lipid absorption by the body, promoting the biosynthesis of fatty acids. However, it was proven that some probiotics, such as *Lactobacillus*, could reduce liver fat deposition by reducing fatty acid absorption in the host intestine[51,52].

Fasting-induced adipocyte factor (FIAF) is a lipoprotein lipase inhibitor, and inhibition of the FIAF gene can significantly reduce body fat deposition. LPL is the key regulatory factor of fatty acid released from lipoprotein in skeletal muscles, the heart, and adipocytes. Under physiological conditions, GM can inhibit FIAF gene expression, promote LPL expression, and decrease TG accumulation in the cells[50,53,54]. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a regulatory factor that serves in maintaining energy balance in the cells, playing a vital part in energy balance. AMPK can be directly phosphorylated by acetyl-CoA carboxylase, which promotes fatty acid oxidation in the tissue and further reduces fat deposition. GM disruption can lead to a reduction in the levels of AMPK in skeletal muscles and the liver, which subsequently leads to inhibition of fatty acid oxidation and excessive accumulation of fat in the liver[50]. Besides, the GM can induce or inhibit angiopoietin-like protein 4 (AGTPL-4) through bile acids to influence LPL activity, thereby affecting fat deposition inside the liver and steatosis outside the liver[42]. A study[55] revealed that giving mice fodders rich in saturated fatty acids, cholesterols, and sugar could increase lipid accumulation in their livers and cause a significant rise in the relative abundance of *Firmicutes* in mice’s intestines. *Firmicutes* are important in the fermentation of resistant starch and dietary fibers and for energy use. The fermentation products are present in the form of SCFAs. On the one hand, SCFAs are essential energy substances of intestinal epithelial cells, which can enhance energy production by promoting sugar and fat synthesis[56]. On the other, SCFAs can alter fatty acid oxidation by inhibiting AMPK, leading to the accumulation of fatty acids in the liver[57]. Moreover, SCFAs are the ligands of G protein-coupled receptors 41 (GPR41). After conjugating to GPR41, SCFAs can mediate leptin production by stimulating GRP41 in mouse adipocytes to regulate energy metabolism[58].

***IR***

Insulin is an important hormone that regulates the steady state of glucose levels in the body. The activation of insulin receptors through phosphorylation initiates the body’s biological response, inclusing increased glucose transport in skeletal muscles and adipose tissues, glycogen synthesis, and lipogenesis. IR reduces the biological effect of insulin, causing hyperinsulinemia (HIS). In turn, HIS leads to abnormal glucose transport and increased glycogenolysis and fatty acid synthesis, promoting MAFLD. Therefore, IR is one of the vital causes of MAFLD[59]. The composition and relative abundance of GM bacteria differ between obese individuals and those who are slim. The GM of obese individuals is mainly composed of *Firmicutes* and *Actinobacteriota, while* *Bacteroidete are* also present but less predominant. As mentioned above, *Firmicutes* with high relative abundance can enhance energy consumption by utilizing more indigestible substances in the intestinal content[60]. An imbalanced ratio of gut bacteria can also disrupt intestinal permeability, leading to increased absorption of LPS. Administration of antibiotics in high-fat diet (HFD) mice has been shown to decrease blood LPS concentration. Furthermore, this reduction in blood LPS concentration contributes to a decrease in adipose tissue inflammation and oxidative stress, which helps prevent adipose tissue hypertrophy and improves glycolipid metabolism parameters of HFD mice[61].

LPS are cell wall components found in gram-negative bacteria and are considered to be a key trigger of IR. Studies[62,63] have shown that IR caused by intestinal endotoxins is mainly mediated by Toll-like receptor 4 (TLR4). In other words, LPS can activate the TLR4 located on the surface of insulin target cells. TLR4 can stimulate hepatocytes to produce inflammatory factors. Stimulating the production of proinflammatory kinase (*e.g.*, JNK) can inhibit the phosphorylation of insulin receptor substrates, thereby inhibiting the insulin signal transduction pathway. Moreover, GM disruption can accelerate the above processes to trigger IR. Reduced insulin sensitivity leads to a decrease in the rate of blood glucose utilization. HIS occurs when islet β cells are in the compensatory hypersecretory state. Further, HIS can disrupt the islet signaling pathway in the liver, forming a vicious circle. IR can alter the regulation of fat by insulin, enhancing steatosis and increasing free fatty acids in the serum. Fatty acids can cause hepatotoxicity. On one side, they can trigger MAFLD *via* various mechanisms, such as causing mitochondrion swelling to increase their permeability, inflammatory invasion, hepatocyte degeneration and necrosis, and induction of cell apoptosis[54]. On the other hand, the liver can transform free fatty acids into TG. Excessive fat will be deposited in the liver when the fat synthesized in the liver exceeds the hepatocyte’s ability for oxidative utilization and synthetic lipoprotein transport, thereby promoting the development of MAFLD[61].

***Increased endogenous ethanol***

The GM can produce and metabolize ethanol. In the relatively hypoxic environment of the intestine, pyruvic acids produced through carbohydrate decomposition can be metabolized by the GM into acetaldehyde, which is further reduced into ethanol[64]. When there is intestinal bacteria overgrowth (Small intestinal bacteria overgrowth often exists in MAFLD) or excessive carbohydrate intake, ethanol metabolism mediated by the GM becomes active[65]. A current study[66] suggested that the primary product of *Enterobacteriaceae* (*e.g.* *Escherichia*) metabolism is ethanol. Other GM, such as *Bacteroides*, *Bifidobacterium,* and *Clostridium*, may also produce ethanol. The ethanol metabolized by GM is also called endogenous ethanol. Under normal conditions, the liver efficiently eliminates endogenous ethanol from the bloodstream of the portal vein through the action of liver alcohol dehydrogenase, catalase, and the ethanol oxidation system. However, in the intestines of MAFLD patients, the abnormal increase of ethanol-producing bacteria promotes and increased production of ethanol. Some patients with MAFLD have a preference for carbohydrates. Due to these two factors, reactive oxygen species are constantly provided to the liver, inducing liver oxidation and triggering inflammation, which is the “second strike” to the liver[66]. A study on children with MAFLD[67] revealed that the relative abundances of *Gammaproteobacteria* and *Prevotella* in these children were significantly higher than in healthy children. For this reason, the production of endogenous ethanol was also distinctly enhanced. Besides, an animal experiment[68] proved that administering antibiotics to alter the GM could reduce the ethanol concentration of the air exhaled by obese mice. A similar conclusion was also confirmed in NASH patients[69], as the air exhaled by NASH patients also had higher ethanol concentrations than healthy individuals. Besides, it was observed that the relative abundance of *Escherichia* in the GM increased significantly, which also confirmed that the increase in endogenous ethanol caused by GM disruption is related to MAFLD.

GM disruption leads to an increase in the relative abundance of bacteria producing ethanol, thereby increasing the ethanol content in the intestines. Ethanol activates various cytokines in the intestinal epithelial cells to increase intestinal wall permeability. Meanwhile, ethanol and acetaldehyde, which are metabolized products, enter the liver through the portal vein. These products can either directly stimulate hepatocytes or activate liver TLR to produce multiple cytokines and inflammatory mediators, resulting in inflammatory liver injury. In addition, the acetaldehyde produced by ethanol through intestinal metabolism can damage the expression of tight-junction proteins between intestinal epithelial cells to alter the intestinal barrier function, leading to bacterial translocation and endotoxemia (Figure 1).

**THE INFLUENCE OF GM ON RELEVANT SIGNALING PATHWAYS**

***FXR signaling pathway***

The FXR signaling pathway is one of the members of the nuclear receptor superfamily, and FXR’s primary function is to regulate bile acid metabolism and enterohepatic circulation. The synthesis, metabolism, and reabsorption of bile acids are regulated by the negative feedback of FXR-relevant signaling pathways in the liver and ileum. Activating FXR can adjust the metabolic state of blood fat, blood glucose, and cholesterol and improve IR[70,71]. Obeticholic acid is an FXR agonist, which inhibits bile acid synthesis and enhances bile salt excretion through the FXR/FGF15/19 signaling pathways, thereby reducing bile acid reabsorption by the liver. Meanwhile, obeticholic acid can regulate the GM, improve intestinal mucosa barrier function, reduce inflammation, decrease the production and translocation of intestinal endotoxin, maintain gut-liver axis balance, and alleviate liver inflammation[70]. GM can also activate FXR in various ways (*e.g.*, *via* increasing fatty acid oxidation). Activated FXR improves glucose metabolism by inhibiting gluconeogenesis and glycogenolysis, reducing fat synthesis, and enhancing skeletal muscle insulin sensitivity. GM disruption can inhibit the transduction of the FXR signaling pathway, leading to an escalation of fatty acid synthesis and the generation of lipid toxicity. This, in turn, further deteriorates hepatic steatosis and promotes the occurrence and progression of MAFLD[72-74].

***GPBAR******signaling pathway***

The mechanism of the GPBAR signaling pathway is similar that of FXR, and these two pathways are closely related to each other[75]. After reabsorption, bile acids induce ileal cells to secrete FGF19 by conjugating to the FXR and GPBAR of ileal cells. FGF19 further conjugates to FGFR4, which reduces CYP7A1 gene expression by activating the JNK and ERK signaling pathways. Therefore, bile acid synthesis is inhibited in negative feedback[23]. GM disruption can alter FXR expression and the transduction of the GPBAR signaling pathway, leading to the production of proinflammatory factors. For example, GPBAR can activate cyclic adenosine monophosphate and epidermal growth factor receptor kinase pathways, resulting in the activation of protein kinase C, which leads to the activation of nuclear factor- κB (NF-κB). Activated NF-κB enhances the expression of numerous proinflammatory factors, such as Il-1β, IL-6, and TNF-α. As a result, this activates the inflammatory immune response of the liver, promoting the occurrence and progression of MAFLD[76,77].

***TLR signaling pathway***

TLR is essential in the gut-liver axis, especially in maintaining the intestinal mucosa barrier. A damaged intestinal mucosa barrier leads to increased permeability, which induces GM transposition. Therefore, a growing number of bacterial metabolites, bacterial substances, and other compounds can enter the liver through the portal vein, causing inflammation, oxidative stress, and lipid deposition. This eventually leads to fat liver injury, which can progress rapidly to liver fibrosis, also called “intestinal leakage”[78]. Bacterial flora translocation increases the endotoxin level in the portal vein or the liver. Pathogen-associated molecular patterns accumulate in the portal vein circulation, promoting the development of liver inflammation[79]. Besides, the increased abundance of pathogenic bacteria caused by GM disruption (or distinct abnormal relative abundance of opportunistic pathogens) lead to the excessive production of LPS. Subsequently, LPS stimulates endothelial cell TLR4 and dendritic cell TLR9 and induces the production of inflammasomes (*e.g.*, NLRP3) and proinflammatory factors (*e.g.*, IL-1β). This further damages intestinal mucosa permeability and reduces liver insulin sensitivity, thereby increasing visceral and subcutaneous fat and promoting the occurrence and progression of MAFLD[80] (Figure 2).

***Immunoregulation***

Liver inflammation is the critical driving factor of MAFLD development, and the gut-liver immune axis plays a vital role in the process. LPS, peptidoglycan (PGN), and bacterial deoxyribonucleic acid (DNA) can be translocated into the liver through the injured intestinal barrier, causing immune cell hyperactivation. LPS can tale advantage of the injured intestinal barrier to enter the liver *via* portal blood flow and induce the activation of inflammasomes[81]. PGN is one of the components of the bacterial cell wall. It is a macromolecule polymerized by acetylglucosamine, acetylmuramic acid, and amino acid short-chain peptide, which plays a role in insulin tolerance[82]. PGN and TLR2 can activate relevant NF-κB and TNF-α signaling pathways after conjugating to nucleotide oligomerization domain (NOD) 1 or NOD2, resulting in liver inflammation. NOD1 can also detect nutrient overload by sensing changing in bacterial microorganisms and promoting the translocation of PGN to regulate the energy metabolism in the gut-liver axis[83]. Bacterial DNA can directly activate immune cells such as macrophages, natural killer cells, B lymphocytes, and dendritic cells. It can also conjugate to TLR9 inside lysosomes *via* endocytosis, activating the NF-κB pathway and secreting inflammatory factors, such as IL-1β, IL-6, and TNF-α[84].

***The bacterial flora therapy of MAFLD***

**Antibiotics:** Research[85] has shown that short-term use of antibiotics can reduce circulating endotoxins and serum transaminases, improving the clinical symptoms of MAFLD patients. Among the antibiotics, the application of rifaximin has received the greatest attention. After rifaximin treatment, the BMI index, transaminase level, and hepatic steatosis degree of MAFLD patients decreased significantly. Even clinical research revealed that rifaximin could reduce the fermentation of carbohydrates and sterols by altering the GM structure, lowering serum inflammatory factors, and improving IR. Antibiotics cocktail (ampicillin, neomycin, metronidazole and vancomycin) can regulate free and conjugated secondary bile acid levels to decrease liver inflammation[86], inhibit intestinal FXR to reduce hepatic steatosis[73], and inhibit the activation of liver macrophage to lower liver inflammation[87]. However, antibiotics play a dual role. Short-term antibiotic treatment can exert therapeutic effects, while long-term application may result in bacterial drug resistance and increase the risk of secondary infection.

**Probiotics:** Clinical experiments on MAFLD patients[88] demonstrated that *Lactobacillus*, *Streptococcus,* and *Bifidobacterium* could significantly reduce the patient’s serum transaminase level. After taking *Lactobacillus bulgaricus* and *Streptococcus thermophilus* for three months, the transaminase level of MAFLD patients improved[89]. The application of *Clostridium butyricum* in clinic settings and MAFLD animal models has shown promising potential in preventing hepatic steatosis[90,91]. In addition, multiple probiotic formulations present better therapeutic effects than one specific bacterial strain. For example, VSL3 (consisting of eight probiotic bacterial strains: *Streptococcus thermophilus*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Bifidobacterium infantis*, *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus acidophilus,* and *Lactobacillus bulgaricus*) has better therapeutic effects than any single bacterial strain[90,92,93]. Studies targeting children with MAFLD[68,94,95] revealed that after VSL3 treatment, patients’ fatty liver disease condition and BMI were distinctly improved. Follow-up research showed that the total quantity and activity of GLP-1 increased after VSL3 treatment. Meanwhile, VSL3 has been found to regulate plasmic peroxide, such as malondialdehyde and 4-hydroxynonenal, leading to therapeutic effects and relieving chronic liver disease. It achieves this by protecting the intestinal barrier and reducing endotoxemia and oxidative/nitroso stress. An animal experiment also verified[96] that probiotics can lower the weight of mice and improve GM disruption. Probiotic intervention can increase the adundance of intestinal anaerobic bacteria (*e.g.*, *Actobacillus* and *Bifidobacterium*). However, this decreases the abundance of *Escherichia* and *Enterococcus*, enhancing the integrity of the intestinal mucosa barrier. Highly expressed TLR4 in the liver improves serum inflammatory factors, liver histology, serum liver enzyme, metabolic index, and glucose metabolism. Evidence indicates that probiotics can decrease liver and systematic inflammation by inhibiting the LPS/TLR4 signal transduction inflammatory cascade.

**Prebiotics:** Fructo-oligosaccharides (FOS) is an indigestible fermentable dietary fiber compound that lowers liver oxidative stress and inflammation by improving intestinal permeability and the integrity of close junctions[97]. Lactulose is another prebiotic that enhances the growth of Bifidobacteria and Lactobacillus and inhibits endotoxic gram-negative bacteria. After taking lactulose for six weeks, the inflammation and liver injury of HFD obese mice was reduced, which was related to lowered LPS level in the circulation[98]. Clinical research[99] has shown that the serum ALT and AST levels of NASH patients decreased significantly after receiving Bifidobacteria and FOS treatments. Combining multiple probiotic bacterial strains (Lactobacillus casei, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacteria breve, Bifidobacteria longum, and Streptococcus thermophilus) and FOS in combination with lifestyle interventions were more beneficial than lifestyle changes alone for MAFLD patients[100]. Combining Bifidobacteria longum and FOS with lifestyle interventions can significantly decrease NASH activity index and liver fat accumulation[101]. The result of a meta-analysis revealed that combining prebiotics could distinctly lower hepatic steatosis and the levels of ALT, AST, LDL, TG, and TC. Moreover, it was also helpful for reducing levels of inflammatory factors such as TNF-α and IR[102]. However, the administration of inulin diet, a soluble fiber, to mice with TLR5 gene knock-out led to an increase in the mice’s bilirubin level, indicating that excessive inulin intake may cause liver injury and even liver cancer[103]. Research has also highlighted that acetate, the fermentation product of inulin in the colon, can provide excess substrate for fat synthesis in the liver, escalating the production of lipids in the liver[104].

***Fecal microbiota transplantation***

The earliest fecal microbiota transplantation (FMT) treatment can be traced back to the book called *A Handbook of Formulas for Emergencies (Zhou Hou Bei Ji Fang)* written by Ge Hong from the Eastern Jin Dynasty (266 A.D. - 317 A.D.) in China. In the book, FMT treatment, also called “Huang Long Soup,” for food poisoning and severe diarrhea was first recorded. Later, Li Shizheng also recorded in *the Compendium of Materia Medica (Bencao Gangmu)* that FMT by oral administration can treat severe diarrhea, fever, vomiting, and constipation[105]. FMT in modern medicine started in the year 1985. Ben Eiseman performed FMT by enema for patients with severe pseudomembranous colitis using feces from the patient’s family member, and three out of the four patients were cured[106]. FMT was officially written into the clinical guidance for recurrent *Clostridium difficile* infection treatment in 2013[107]. As research progresses, numerous pieces of evidence support the potential efficacy of FMT in treating GM-related liver disease and metabolic disorders such as MAFLD. Studies have shown[108,109] that transplanting the GM of slim or obese mice can induce the recipient to have a phenotype similar to that of the host. The bacterial flora from slim mice can make obese mice lose weight. Six weeks after overweight patients with metabolic syndrome received bacterial flora from the slim individuals, the sensitivity of their liver and peripheral insulin was significantly enhanced[110]. Several studies have demonstrated[111-114] that the therapeutic effects of FMT on patients with T2DM and ulcerative colitis were related to GM steady state, normal blood fat level, and IR improvement. Feces from HFD-responsive and non-responsive mice were transplanted into germ-free mice. Mice receiving bacterial flora from the responsive group developed steatosis and exhibited increased relative abundance of *Barnesiella* and *Roseburia*. In contrast, the non-responsive group showed an increased relative abundance of *Allobaculum* in their bacterial flora[55]. In addition, FMT could significantly restore the GM disruption in NASH mice models induced by HFD by increasing the relative abundance of probiotics (*e.g.*, *Christensen* and *Lactobacillus*) and mitigate endotoxemia, hepatic steatosis, and inflammation[115]. In a RCT admitting 75 MAFLD patients, Xue *et al*[116] divided the patients into an FMT group (47 individuals) and a non-FMT group (28 individuals). The patients from the non-FMT group took oral probiotics, while the FMT group received three FMT enemas within three days. Both groups received a healthy diet and conducted exercise regularly for over 40 min. After treatment for one month, it was found that FMT lead to a reduction in liver fat deposition by improving the GM disruption, lowering the incidence of fatty liver disease. Moreover, the GM reconstruction effect of FMT on thin-type MAFLD patients was better compared to obese MAFLD patients. FMT can be administered through various methods to meet the requirements of different patients, including *via* nasogastric tubes, nasojejunal feeding tubes, gastroscopes, coloscopes, colonic catheters, retention enema, and capsules. However, FMT may pose certains risks. For example, the GM condition of different providers may affect the therapeutic effect, infection may occur during the transplantation, and it is uncertain how the GM can be effectively colonized in the patient’s intestine. All these problems require further exploration.

***Phage therapy***

Phages are viruses that specifically infect and kill bacteria. They have the ability to adapt and evolve, enabling them to overcome the developing defensive mechanism of bacteria. Phages do not have the same mechanism as antibiotics. Thus, antibiotic resistance does not affect phages, and bacteria with high antibiotic resistance can still be inhibited by phages[117]. By studying the changes in bacterial composition and relative abundance, bacteria can be targeted for eradication using phages specific to that bacteria, after determining the mechanism by which a specific bacterium affects the onset or progression of MAFLD or whether the two are causally related. Its adverse effects on MAFLD can be eliminated without affecting the normal function of other bacteria[118]. For example, using phages for the targeted eradication of high-alcohol-producing *Klebsiella pneumoniae* (HiAlc-Kpn, found in over 60% of MAFLD patients, can produce enormous amounts of alcohol and is the leading cause of the bacterial auto-brewery syndrome) can effectively mitigate the bacterial auto-brewery syndrome of MAFLD model mice[119]. An analysis was conducted on feces samples of NASH patients and healthy people. The *Enterococcus faecalis* level in the feces samples of alcoholic hepatitis patients is 300 higher than in healthy subjects. The relative abundance of *Enterococcus faecalis* significantly increased in approximately 80% of feces samples from patients with alcoholic hepatitis. Further analysis showed that a gene which can encode cytolysin existed in approximately 30% of *Enterococcus faecalis* species[118]. Alcoholic hepatitis mouse models were built using a high-alcohol diet. After being transplanted with a feces sample containing cytolysin, these alcoholic hepatitis mice developed specific hepatocyte injury and died. However, alcoholic hepatitis mice transplanted with samples without cytolysin did not develop liver injury. Targeting the phages specific to *Enterococcus faecalis* can effectively reduce the abundance of this bacterium, especially strains producing cytolysin. This targeted approach has shown promising results in lowering the degree of liver injury in alcoholic hepatitis mice, serving as a protective measure[118]. This is a critical attempt at phage therapy in the gut-liver axis, indicating the potential application value of phage therapy in MAFLD treatment (Figure 3).

In addition to the antibiotics mentioned above, probiotics, FMT, and other therapies that directly target GM, there is growing evidence that modifying dietary habits and increasing physicial exercise both improve MAFLD and the GM disorder in MAFLD. High-fat and high-sugar diets can change the GM structure in different ways[120]. HFD mice have a greater abundance of *Firmicutes,* while mice with a high-sugar diet have a lower relative abundance of *Firmicutes* and *Bacteroides*, which is closely related to the onset and development of MAFLD. High-fructose intake will up-regulate the re-synthesis of fat and inhibit the oxidation of fatty acid β. It can cause hepatic steatosis, induce inflammation through the TLR signaling pathway, and release inflammatory factors. High-fructose intake can also reduce insulin sensitivity. HFD decreases the number of intestinal probiotics *Bifidobacteria* and bacteria that produce butyric acid. It also enhances intestinal permeability, LPS translocation, and chronic systemic inflammation. High saturated fatty acid intake can lower the GM diversity and increase the ratio of *Firmicutes* to *Bacteroides*, result in weight gain, and increase plasmic insulin and TG content[121]. In MAFLD mice induced by HFD, six-week HFD increases *Firmicutes* abundance and decreases *Bacteroides* abundance. The ratio of *Firmicutes* to *Bacteroides was* significantly enhanced, and the ratio was maitained till the end of the experiment. However, exercise can improve GM disorder resulting from a HFD. This is achieved by changing the ratio of the two bacteria via reducing *Firmicutes* abundance and increasing *Bacteroides* abundance[122]*.* Exercise distinctly alleviates GM disruption caused by HFD and restores the intestinal mucosa barrier function to a certain extent. The relative abundance of some GM reaches a level similar to normal rats. Meanwhile, exercise also significantly downregulated the expression of FXR and CD36 in the liver, indicating improvements in liver lipid metabolism[123]. Research combining exercise and lycium barbarum polysaccharide also found that aerobic exercise restores the close junction of the colon and ileum and improves intestinal mucosa permeability by enhancing ZO-1 expression. Relevant indicators such as intestinal LPS, liver LPS binding protein, and inflammatory factors are also downregulated[123]. However, research on the effects of exercise on GM in MAFLD patients is relatively sparse. Although animal experiments have demonstrated that exercise can improve MAFLD symptoms by restoring GM, more clinical experiments are needed.

**CONCLUSION**

Generally, with the increase in metabolic diseases such as obesity, the incidence of MADLF also increases yearly. Many clinical studies and animal experiments have demonstrated that the GM is vital in the onset and development of MAFLD, but most studies remain at a phenomenal level. There is no definitive conclusion regarding the “cause” and the “effect” of GM disorder and MAFLD. However, the efficacy of treatments targeting GM, such as probiotics and FMT, has been confirmed in both clinical applications and basic research without reporting severe adverse events. There is also a wide range of opinions on how many bacterial flora therapies are used to improve MAFLD. A healthy lifestyle and good dietary habits are still the foundation of MAFLD treatments. Comprehensive therapies combing bacterial flora therapy certainly have good prospects, but continuous efforts are still needed to design high-quality long-term clinical experiments. Meanwhile, histological studies combining multi-omics, such as metagenome, metabolome, and proteome, are needed. In the future, it is expected that GM can better help in the diagnosis, treatment, and prognosis evaluation.

**ACKNOWLEDGEMENTS**

All the authors thank Yu-Jie Liang for helping to design the high-quality figures. Moreover, we thank Li-fen Ren and Ji-wen Xu for their logistic support in completing this paper. Finally, we would like to express our special gratitude for their dedication.

**REFERENCES**

1 **Michelotti GA**, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 656-665 [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183]

2 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

3 **Younossi Z**, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 11-20 [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109]

4 **Fujimura KE**, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. *Expert Rev Anti Infect Ther* 2010; **8**: 435-454 [PMID: 20377338 DOI: 10.1586/eri.10.14]

5 **Rinninella E**, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* 2019; **7** [PMID: 30634578 DOI: 10.3390/microorganisms7010014]

6 **Wang L**, Cao ZM, Zhang LL, Li JM, Lv WL. The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective. *Front Immunol* 2022; **13**: 923599 [PMID: 35911738 DOI: 10.3389/fimmu.2022.923599]

7 **Christovich A**, Luo XM. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. *Front Immunol* 2022; **13**: 946248 [PMID: 35833129 DOI: 10.3389/fimmu.2022.946248]

8 **Fang J**, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, Yu WY. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. *Front Cell Infect Microbiol* 2022; **12**: 997018 [PMID: 36425787 DOI: 10.3389/fcimb.2022.997018]

9 **Fukui H**. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? *Diseases* 2019; **7** [PMID: 31726747 DOI: 10.3390/diseases7040058]

10 **Zeng H**, Larson KJ, Cheng WH, Bukowski MR, Safratowich BD, Liu Z, Hakkak R. Advanced liver steatosis accompanies an increase in hepatic inflammation, colonic, secondary bile acids and Lactobacillaceae/Lachnospiraceae bacteria in C57BL/6 mice fed a high-fat diet. *J Nutr Biochem* 2020; **78**: 108336 [PMID: 32004929 DOI: 10.1016/j.jnutbio.2019.108336]

11 **Lechner S**, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. *Dig Dis Sci* 2020; **65**: 897-905 [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0]

12 **Lee H**, An J, Kim J, Choi D, Song Y, Lee CK, Kong H, Kim SB, Kim K. A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice *via* GLP-1 Receptor. *Front Microbiol* 2022; **13**: 858192 [PMID: 35655996 DOI: 10.3389/fmicb.2022.858192]

13 **Jiao A**, Yu B, He J, Yu J, Zheng P, Luo Y, Luo J, Mao X, Chen D. Short chain fatty acids could prevent fat deposition in pigs *via* regulating related hormones and genes. *Food Funct* 2020; **11**: 1845-1855 [PMID: 32067021 DOI: 10.1039/c9fo02585e]

14 **Zhang S**, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. *Obes Rev* 2021; **22**: e13316 [PMID: 34279051 DOI: 10.1111/obr.13316]

15 **Wahlström A**, Sayin SI, Marschall HU, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016; **24**: 41-50 [PMID: 27320064 DOI: 10.1016/j.cmet.2016.05.005]

16 **Ferslew BC**, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer KL, Barritt AS 4th. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. *Dig Dis Sci* 2015; **60**: 3318-3328 [PMID: 26138654 DOI: 10.1007/s10620-015-3776-8]

17 **Swann JR**, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. *Proc Natl Acad Sci U S A* 2011; **108 Suppl 1**: 4523-4530 [PMID: 20837534 DOI: 10.1073/pnas.1006734107]

18 **Jia W**, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 111-128 [PMID: 29018272 DOI: 10.1038/nrgastro.2017.119]

19 **Sinha SR**, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G, Namkoong H, Bittinger K, Fischbach MA, Sonnenburg JL, Habtezion A. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. *Cell Host Microbe* 2020; **27**: 659-670.e5 [PMID: 32101703 DOI: 10.1016/j.chom.2020.01.021]

20 **Ramírez-Pérez O**, Cruz-Ramón V, Chinchilla-López P, Méndez-Sánchez N. The Role of the Gut Microbiota in Bile Acid Metabolism. *Ann Hepatol* 2017; **16**: s15-s20 [PMID: 29080339 DOI: 10.5604/01.3001.0010.5494]

21 **Schmid A**, Schlegel J, Thomalla M, Karrasch T, Schäffler A. Evidence of functional bile acid signaling pathways in adipocytes. *Mol Cell Endocrinol* 2019; **483**: 1-10 [PMID: 30543876 DOI: 10.1016/j.mce.2018.12.006]

22 **Selwyn FP**, Csanaky IL, Zhang Y, Klaassen CD. Importance of Large Intestine in Regulating Bile Acids and Glucagon-Like Peptide-1 in Germ-Free Mice. *Drug Metab Dispos* 2015; **43**: 1544-1556 [PMID: 26199423 DOI: 10.1124/dmd.115.065276]

23 **Sayin SI**, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* 2013; **17**: 225-235 [PMID: 23395169 DOI: 10.1016/j.cmet.2013.01.003]

24 **Wahlström A**, Kovatcheva-Datchary P, Ståhlman M, Khan MT, Bäckhed F, Marschall HU. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. *J Lipid Res* 2017; **58**: 412-419 [PMID: 27956475 DOI: 10.1194/jlr.M072819]

25 **Out C**, Patankar JV, Doktorova M, Boesjes M, Bos T, de Boer S, Havinga R, Wolters H, Boverhof R, van Dijk TH, Smoczek A, Bleich A, Sachdev V, Kratky D, Kuipers F, Verkade HJ, Groen AK. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption *via* Gata4. *J Hepatol* 2015; **63**: 697-704 [PMID: 26022694 DOI: 10.1016/j.jhep.2015.04.030]

26 **Clements WD**, Parks R, Erwin P, Halliday MI, Barr J, Rowlands BJ. Role of the gut in the pathophysiology of extrahepatic biliary obstruction. *Gut* 1996; **39**: 587-593 [PMID: 8944570 DOI: 10.1136/gut.39.4.587]

27 **Lorenzo-Zúñiga V**, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. *Hepatology* 2003; **37**: 551-557 [PMID: 12601352 DOI: 10.1053/jhep.2003.50116]

28 **Buffie CG**, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. *Nature* 2015; **517**: 205-208 [PMID: 25337874 DOI: 10.1038/nature13828]

29 **De Boever P**, Wouters R, Verschaeve L, Berckmans P, Schoeters G, Verstraete W. Protective effect of the bile salt hydrolase-active Lactobacillus reuteri against bile salt cytotoxicity. *Appl Microbiol Biotechnol* 2000; **53**: 709-714 [PMID: 10919331 DOI: 10.1007/s002530000330]

30 **Baron EJ**, Summanen P, Downes J, Roberts MC, Wexler H, Finegold SM. Bilophila wadsworthia, gen. nov. and sp. nov., a unique gram-negative anaerobic rod recovered from appendicitis specimens and human faeces. *J Gen Microbiol* 1989; **135**: 3405-3411 [PMID: 2636263 DOI: 10.1099/00221287-135-12-3405]

31 **Sherriff JL**, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes. *Adv Nutr* 2016; **7**: 5-13 [PMID: 26773011 DOI: 10.3945/an.114.007955]

32 **Takaki A**, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). *Int J Mol Sci* 2014; **15**: 7352-7379 [PMID: 24786095 DOI: 10.3390/ijms15057352]

33 **Ossani GP**, Marcotegui AR, Uceda AM, Monserrat AJ, Lago NR, Perazzo JC. Menhaden Oil Rich Diet and Experimental Renal Damage Due to Ischemia Reperfusion. *J Oleo Sci* 2017; **66**: 1157-1159 [PMID: 28924087 DOI: 10.5650/jos.ess17094]

34 **Akesson B**, Fehling C, Jägerstad M. Lipid composition and metabolism in liver and brain of vitamin B12-deficient rat sucklings. *Br J Nutr* 1979; **41**: 263-274 [PMID: 427079 DOI: 10.1079/bjn19790035]

35 **Corbin KD**, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. *Curr Opin Gastroenterol* 2012; **28**: 159-165 [PMID: 22134222 DOI: 10.1097/MOG.0b013e32834e7b4b]

36 **Spencer MD**, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. *Gastroenterology* 2011; **140**: 976-986 [PMID: 21129376 DOI: 10.1053/j.gastro.2010.11.049]

37 **Romano KA**, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. *mBio* 2015; **6**: e02481 [PMID: 25784704 DOI: 10.1128/mBio.02481-14]

38 **Martínez-del Campo A**, Bodea S, Hamer HA, Marks JA, Haiser HJ, Turnbaugh PJ, Balskus EP. Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. *mBio* 2015; **6** [PMID: 25873372 DOI: 10.1128/mBio.00042-15]

39 **Tan X**, Liu Y, Long J, Chen S, Liao G, Wu S, Li C, Wang L, Ling W, Zhu H. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. *Mol Nutr Food Res* 2019; **63**: e1900257 [PMID: 31095863 DOI: 10.1002/mnfr.201900257]

40 **Craciun S**, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. *Proc Natl Acad Sci U S A* 2012; **109**: 21307-21312 [PMID: 23151509 DOI: 10.1073/pnas.1215689109]

41 **Geiger O**, López-Lara IM, Sohlenkamp C. Phosphatidylcholine biosynthesis and function in bacteria. *Biochim Biophys Acta* 2013; **1831**: 503-513 [PMID: 22922101 DOI: 10.1016/j.bbalip.2012.08.009]

42 **Qian Y**, Fan JG. Obesity, fatty liver and liver cancer. *Hepatobiliary Pancreat Dis Int* 2005; **4**: 173-177 [PMID: 15908310]

43 **Radziejewska A**, Muzsik A, Milagro FI, Martínez JA, Chmurzynska A. One-Carbon Metabolism and Nonalcoholic Fatty Liver Disease: The Crosstalk between Nutrients, Microbiota, and Genetics. *Lifestyle Genom* 2020; **13**: 53-63 [PMID: 31846961 DOI: 10.1159/000504602]

44 **Wang D**, Yan S, Yan J, Teng M, Meng Z, Li R, Zhou Z, Zhu W. Effects of triphenyl phosphate exposure during fetal development on obesity and metabolic dysfunctions in adult mice: Impaired lipid metabolism and intestinal dysbiosis. *Environ Pollut* 2019; **246**: 630-638 [PMID: 30605818 DOI: 10.1016/j.envpol.2018.12.053]

45 **Jepsen MM**, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. *Expert Opin Emerg Drugs* 2021; **26**: 231-243 [PMID: 34176426 DOI: 10.1080/14728214.2021.1947240]

46 **Soares JB**, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. *Hepatol Int* 2010; **4**: 659-672 [PMID: 21286336 DOI: 10.1007/s12072-010-9219-x]

47 **Arias N**, Arboleya S, Allison J, Kaliszewska A, Higarza SG, Gueimonde M, Arias JL. The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. *Nutrients* 2020; **12** [PMID: 32764281 DOI: 10.3390/nu12082340]

48 **Maier TV**, Lucio M, Lee LH, VerBerkmoes NC, Brislawn CJ, Bernhardt J, Lamendella R, McDermott JE, Bergeron N, Heinzmann SS, Morton JT, González A, Ackermann G, Knight R, Riedel K, Krauss RM, Schmitt-Kopplin P, Jansson JK. Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome. *mBio* 2017; **8** [PMID: 29042495 DOI: 10.1128/mBio.01343-17]

49 **Iwaki M**, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2021; **36**: 2275-2284 [PMID: 33709477 DOI: 10.1111/jgh.15487]

50 **Zhi C**, Huang J, Wang J, Cao H, Bai Y, Guo J, Su Z. Connection between gut microbiome and the development of obesity. *Eur J Clin Microbiol Infect Dis* 2019; **38**: 1987-1998 [PMID: 31367997 DOI: 10.1007/s10096-019-03623-x]

51 **Khan A**, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. *Int J Biol Sci* 2021; **17**: 818-833 [PMID: 33767591 DOI: 10.7150/ijbs.56214]

52 **Jang HR**, Park HJ, Kang D, Chung H, Nam MH, Lee Y, Park JH, Lee HY. A protective mechanism of probiotic Lactobacillus against hepatic steatosis *via* reducing host intestinal fatty acid absorption. *Exp Mol Med* 2019; **51**: 1-14 [PMID: 31409765 DOI: 10.1038/s12276-019-0293-4]

53 **Zhao Y**, Zhang X. Interactions of tea polyphenols with intestinal microbiota and their implication for anti-obesity. *J Sci Food Agric* 2020; **100**: 897-903 [PMID: 31588996 DOI: 10.1002/jsfa.10049]

54 **Caricilli AM**, Saad MJ. The role of gut microbiota on insulin resistance. *Nutrients* 2013; **5**: 829-851 [PMID: 23482058 DOI: 10.3390/nu5030829]

55 **Le Roy T**, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gérard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. *Gut* 2013; **62**: 1787-1794 [PMID: 23197411 DOI: 10.1136/gutjnl-2012-303816]

56 **Schönfeld P**, Wojtczak L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. *J Lipid Res* 2016; **57**: 943-954 [PMID: 27080715 DOI: 10.1194/jlr.R067629]

57 **Turnbaugh PJ**, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; **444**: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]

58 **Secor JD**, Fligor SC, Tsikis ST, Yu LJ, Puder M. Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease. *Front Physiol* 2021; **12**: 656441 [PMID: 33897464 DOI: 10.3389/fphys.2021.656441]

59 **Kosmidou M**, Milionis H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. *Minerva Endocrinol* 2017; **42**: 109-121 [PMID: 27990792 DOI: 10.23736/S0391-1977.16.02562-1]

60 **Di Ciaula A**, Bonfrate L, Portincasa P. The role of microbiota in nonalcoholic fatty liver disease. *Eur J Clin Invest* 2022; **52**: e13768 [PMID: 35294774 DOI: 10.1111/eci.13768]

61 **Ovadia H**, Haim Y, Nov O, Almog O, Kovsan J, Bashan N, Benhar M, Rudich A. Increased adipocyte S-nitrosylation targets anti-lipolytic action of insulin: relevance to adipose tissue dysfunction in obesity. *J Biol Chem* 2011; **286**: 30433-30443 [PMID: 21724851 DOI: 10.1074/jbc.M111.235945]

62 **Zhang CH**, Sheng JQ, Sarsaiya S, Shu FX, Liu TT, Tu XY, Ma GQ, Xu GL, Zheng HX, Zhou LF. The anti-diabetic activities, gut microbiota composition, the anti-inflammatory effects of Scutellaria-coptis herb couple against insulin resistance-model of diabetes involving the toll-like receptor 4 signaling pathway. *J Ethnopharmacol* 2019; **237**: 202-214 [PMID: 30807814 DOI: 10.1016/j.jep.2019.02.040]

63 **Saad MJ**, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. *Physiology (Bethesda)* 2016; **31**: 283-293 [PMID: 27252163 DOI: 10.1152/physiol.00041.2015]

64 **Patel D**, Sharma D, Mandal P. Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease. *Mediators Inflamm* 2022; **2022**: 4230599 [PMID: 35633655 DOI: 10.1155/2022/4230599]

65 **Zhu L**, Baker RD, Zhu R, Baker SS. Gut microbiota produce alcohol and contribute to NAFLD. *Gut* 2016; **65**: 1232 [PMID: 26984853 DOI: 10.1136/gutjnl-2016-311571]

66 **Sarkola T**, Eriksson CJ. Effect of 4-methylpyrazole on endogenous plasma ethanol and methanol levels in humans. *Alcohol Clin Exp Res* 2001; **25**: 513-516 [PMID: 11329490]

67 **Michail S**, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. *FEMS Microbiol Ecol* 2015; **91**: 1-9 [PMID: 25764541 DOI: 10.1093/femsec/fiu002]

68 **Alisi A**, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2014; **39**: 1276-1285 [PMID: 24738701 DOI: 10.1111/apt.12758]

69 **Zhu L**, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology* 2013; **57**: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]

70 **Zhang DY**, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ. The protective effect and mechanism of the FXR agonist obeticholic acid *via* targeting gut microbiota in non-alcoholic fatty liver disease. *Drug Des Devel Ther* 2019; **13**: 2249-2270 [PMID: 31308634 DOI: 10.2147/DDDT.S207277]

71 **Gonzalez FJ**, Jiang C, Patterson AD. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. *Gastroenterology* 2016; **151**: 845-859 [PMID: 27639801 DOI: 10.1053/j.gastro.2016.08.057]

72 **Wieland A**, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2015; **42**: 1051-1063 [PMID: 26304302 DOI: 10.1111/apt.13376]

73 **Jiang C**, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. *J Clin Invest* 2015; **125**: 386-402 [PMID: 25500885 DOI: 10.1172/JCI76738]

74 **Dawson PA**, Karpen SJ. Intestinal transport and metabolism of bile acids. *J Lipid Res* 2015; **56**: 1085-1099 [PMID: 25210150 DOI: 10.1194/jlr.R054114]

75 **Portincasa P**, Di Ciaula A, Garruti G, Vacca M, De Angelis M, Wang DQ. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome. *Nutrients* 2020; **12** [PMID: 33266235 DOI: 10.3390/nu12123709]

76 **Guo C**, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, Zheng M, Zhang X, Xia D, Ke Y, Lu L, Wang D. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. *Immunity* 2016; **45**: 802-816 [PMID: 27692610 DOI: 10.1016/j.immuni.2016.09.008]

77 **Chen Z**, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. *Lipids Health Dis* 2017; **16**: 203 [PMID: 29037210 DOI: 10.1186/s12944-017-0572-9]

78 **Plaza-Díaz J**, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. *Int J Mol Sci* 2020; **21** [PMID: 33171747 DOI: 10.3390/ijms21218351]

79 **Arab JP**, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. *Hepatol Res* 2020; **50**: 407-418 [PMID: 31840358 DOI: 10.1111/hepr.13473]

80 **Fei N**, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. *mBio* 2020; **11** [PMID: 32019793 DOI: 10.1128/mBio.03263-19]

81 **Ciesielska A**, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. *Cell Mol Life Sci* 2021; **78**: 1233-1261 [PMID: 33057840 DOI: 10.1007/s00018-020-03656-y]

82 **Dziarski R**, Gupta D. Peptidoglycan recognition in innate immunity. *J Endotoxin Res* 2005; **11**: 304-310 [PMID: 16263004 DOI: 10.1179/096805105X67256]

83 **Zeuthen LH**, Fink LN, Frøkiaer H. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. *Immunology* 2008; **124**: 489-502 [PMID: 18217947 DOI: 10.1111/j.1365-2567.2007.02800.x]

84 **Minton K**. LC3 anchors TLR9 signalling. *Nat Rev Immunol* 2018; **18**: 418-419 [PMID: 29752467 DOI: 10.1038/s41577-018-0019-1]

85 **Gangarapu V**, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 2015; **27**: 840-845 [PMID: 26043290 DOI: 10.1097/MEG.0000000000000348]

86 **Jena PK**, Sheng L, Liu HX, Kalanetra KM, Mirsoian A, Murphy WJ, French SW, Krishnan VV, Mills DA, Wan YY. Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment. *Am J Pathol* 2017; **187**: 1800-1813 [PMID: 28711154 DOI: 10.1016/j.ajpath.2017.04.019]

87 **Yamada S**, Kamada N, Amiya T, Nakamoto N, Nakaoka T, Kimura M, Saito Y, Ejima C, Kanai T, Saito H. Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. *BMC Gastroenterol* 2017; **17**: 136 [PMID: 29187142 DOI: 10.1186/s12876-017-0689-3]

88 **Paolella G**, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. *World J Gastroenterol* 2014; **20**: 15518-15531 [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518]

89 **Aller R**, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. *Eur Rev Med Pharmacol Sci* 2011; **15**: 1090-1095 [PMID: 22013734]

90 **Seo M**, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, Katayama S, Alpers DH, Komoda T. Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. *Dig Dis Sci* 2013; **58**: 3534-3544 [PMID: 24166662 DOI: 10.1007/s10620-013-2879-3]

91 **Endo H**, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. *PLoS One* 2013; **8**: e63388 [PMID: 23696823 DOI: 10.1371/journal.pone.0063388]

92 **Timmerman HM**, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics--A comparison of functionality and efficacy. *Int J Food Microbiol* 2004; **96**: 219-233 [PMID: 15454313 DOI: 10.1016/j.ijfoodmicro.2004.05.012]

93 **Salminen S**, Nybom S, Meriluoto J, Collado MC, Vesterlund S, El-Nezami H. Interaction of probiotics and pathogens--benefits to human health? *Curr Opin Biotechnol* 2010; **21**: 157-167 [PMID: 20413293 DOI: 10.1016/j.copbio.2010.03.016]

94 **Meroni M**, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? *Int J Mol Sci* 2019; **20** [PMID: 31540133 DOI: 10.3390/ijms20184568]

95 **Loguercio C**, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. *J Clin Gastroenterol* 2005; **39**: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]

96 **Xue L**, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, Geng Y. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. *Sci Rep* 2017; **7**: 45176 [PMID: 28349964 DOI: 10.1038/srep45176]

97 **Koopman N**, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2019; **50**: 628-639 [PMID: 31373710 DOI: 10.1111/apt.15416]

98 **Yan F**, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterology* 2007; **132**: 562-575 [PMID: 17258729 DOI: 10.1053/j.gastro.2006.11.022]

99 **Jafarpour D**, Shekarforoush SS, Ghaisari HR, Nazifi S, Sajedianfard J, Eskandari MH. Protective effects of synbiotic diets of Bacillus coagulans, Lactobacillus plantarum and inulin against acute cadmium toxicity in rats. *BMC Complement Altern Med* 2017; **17**: 291 [PMID: 28583137 DOI: 10.1186/s12906-017-1803-3]

100 **Eslamparast T**, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. *Am J Clin Nutr* 2014; **99**: 535-542 [PMID: 24401715 DOI: 10.3945/ajcn.113.068890]

101 **Malaguarnera M**, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. *Dig Dis Sci* 2012; **57**: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]

102 **Liu L**, Li P, Liu Y, Zhang Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. *Dig Dis Sci* 2019; **64**: 3402-3412 [PMID: 31203554 DOI: 10.1007/s10620-019-05699-z]

103 **Singh V**, Yeoh BS, Chassaing B, Xiao X, Saha P, Aguilera Olvera R, Lapek JD Jr, Zhang L, Wang WB, Hao S, Flythe MD, Gonzalez DJ, Cani PD, Conejo-Garcia JR, Xiong N, Kennett MJ, Joe B, Patterson AD, Gewirtz AT, Vijay-Kumar M. Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. *Cell* 2018; **175**: 679-694.e22 [PMID: 30340040 DOI: 10.1016/j.cell.2018.09.004]

104 **Chambers ES**, Byrne CS, Rugyendo A, Morrison DJ, Preston T, Tedford C, Bell JD, Thomas L, Akbar AN, Riddell NE, Sharma R, Thursz MR, Manousou P, Frost G. The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. *Diabetes Obes Metab* 2019; **21**: 372-376 [PMID: 30098126 DOI: 10.1111/dom.13500]

105 **Zhang F**, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. *Protein Cell* 2018; **9**: 462-473 [PMID: 29691757 DOI: 10.1007/s13238-018-0541-8]

106 **Eiseman B**, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. *Surgery* 1958; **44**: 854-859 [PMID: 13592638]

107 **Surawicz CM**, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *Am J Gastroenterol* 2013; **108**: 478-98; quiz 499 [PMID: 23439232 DOI: 10.1038/ajg.2013.4]

108 **Walker AW**, Parkhill J. Microbiology. Fighting obesity with bacteria. *Science* 2013; **341**: 1069-1070 [PMID: 24009379 DOI: 10.1126/science.1243787]

109 **Ridaura VK**, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* 2013; **341**: 1241214 [PMID: 24009397 DOI: 10.1126/science.1241214]

110 **Vrieze A**, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012; **143**: 913-6.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]

111 **Kootte RS**, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, Knop FK, Blaak EE, Zhao J, Smidt H, Harms AC, Hankemeijer T, Bergman JJGHM, Romijn HA, Schaap FG, Olde Damink SWM, Ackermans MT, Dallinga-Thie GM, Zoetendal E, de Vos WM, Serlie MJ, Stroes ESG, Groen AK, Nieuwdorp M. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* 2017; **26**: 611-619.e6 [PMID: 28978426 DOI: 10.1016/j.cmet.2017.09.008]

112 **de Groot P**, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, Herrema H, Ackermans M, Serlie MJM, de Brauw M, Levels JHM, Sales A, Gerdes VE, Ståhlman M, Schimmel AWM, Dallinga-Thie G, Bergman JJ, Holleman F, Hoekstra JBL, Groen A, Bäckhed F, Nieuwdorp M. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut* 2020; **69**: 502-512 [PMID: 31147381 DOI: 10.1136/gutjnl-2019-318320]

113 **Cai TT**, Ye XL, Yong HJ, Song B, Zheng XL, Cui BT, Zhang FM, Lu YB, Miao H, Ding DF. Fecal microbiota transplantation relieve painful diabetic neuropathy: A case report. *Medicine (Baltimore)* 2018; **97**: e13543 [PMID: 30558014 DOI: 10.1097/MD.0000000000013543]

114 **Anderson JL**, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; **36**: 503-516 [PMID: 22827693 DOI: 10.1111/j.1365-2036.2012.05220.x]

115 **Zhou D**, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice *via* beneficial regulation of gut microbiota. *Sci Rep* 2017; **7**: 1529 [PMID: 28484247 DOI: 10.1038/s41598-017-01751-y]

116 **Xue L**, Deng Z, Luo W, He X, Chen Y. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. *Front Cell Infect Microbiol* 2022; **12**: 759306 [PMID: 35860380 DOI: 10.3389/fcimb.2022.759306]

117 **Xu HM**, Xu WM, Zhang L. Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases. *Int J Clin Pract* 2022; **2022**: 4913146 [PMID: 36263241 DOI: 10.1155/2022/4913146]

118 **Duan Y**, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. *Nature* 2019; **575**: 505-511 [PMID: 31723265 DOI: 10.1038/s41586-019-1742-x]

119 **Yuan J**, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W, Li B, Li H, Lin W, Tian C, Zhao J, Han J, An D, Zhang Q, Wei H, Zheng M, Ma X, Li W, Chen X, Zhang Z, Zeng H, Ying S, Wu J, Yang R, Liu D. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. *Cell Metab* 2019; **30**: 675-688.e7 [PMID: 31543403 DOI: 10.1016/j.cmet.2019.08.018]

120 **Liu JP**, Zou WL, Chen SJ, Wei HY, Yin YN, Zou YY, Lu FG. Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. *World J Gastroenterol* 2016; **22**: 7353-7364 [PMID: 27621581 DOI: 10.3748/wjg.v22.i32.7353]

121 **de Wit N**, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, de Vogel-van den Bosch J, Kleerebezem M, Müller M, van der Meer R. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G589-G599 [PMID: 22700822 DOI: 10.1152/ajpgi.00488.2011]

122 **Denou E**, Marcinko K, Surette MG, Steinberg GR, Schertzer JD. High-intensity exercise training increases the diversity and metabolic capacity of the mouse distal gut microbiota during diet-induced obesity. *Am J Physiol Endocrinol Metab* 2016; **310**: E982-E993 [PMID: 27117007 DOI: 10.1152/ajpendo.00537.2015]

123 **Gao LL**, Ma JM, Fan YN, Zhang YN, Ge R, Tao XJ, Zhang MW, Gao QH, Yang JJ. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. *Int J Biol Macromol* 2021; **183**: 1379-1392 [PMID: 33992651 DOI: 10.1016/j.ijbiomac.2021.05.066]

124 **Mouzaki M**, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology* 2013; **58**: 120-127 [PMID: 23401313 DOI: 10.1002/hep.26319]

125 **Raman M**, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2013; **11**: 868-75.e1-3 [PMID: 23454028 DOI: 10.1016/j.cgh.2013.02.015]

126 **Wong VW**, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. *PLoS One* 2013; **8**: e62885 [PMID: 23638162 DOI: 10.1371/journal.pone.0062885]

127 **Jiang W**, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. *Sci Rep* 2015; **5**: 8096 [PMID: 25644696 DOI: 10.1038/srep08096]

128 **Boursier J**, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology* 2016; **63**: 764-775 [PMID: 26600078 DOI: 10.1002/hep.28356]

129 **Del Chierico F**, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B, Miccheli A, Alisi A, Putignani L. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. *Hepatology* 2017; **65**: 451-464 [PMID: 27028797 DOI: 10.1002/hep.28572]

130 **Wang B**, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. *Sci Rep* 2016; **6**: 32002 [PMID: 27550547 DOI: 10.1038/srep32002]

131 **Shen F**, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. *Hepatobiliary Pancreat Dis Int* 2017; **16**: 375-381 [PMID: 28823367 DOI: 10.1016/S1499-3872(17)60019-5]

132 **Da Silva HE**, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. *Sci Rep* 2018; **8**: 1466 [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9]

133 **Nobili V**, Putignani L, Mosca A, Del Chierico F, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M, Drago L. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? *Arch Med Sci* 2018; **14**: 81-87 [PMID: 29379536 DOI: 10.5114/aoms.2016.62150]

134 **Duarte SMB**, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada LSRR, de Barros Costa FG, Toda K, Mazo DFC, Sabino EC, Carrilho FJ, Gasbarrini A, Oliveira CP. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. *Nutr Metab Cardiovasc Dis* 2018; **28**: 369-384 [PMID: 29482963 DOI: 10.1016/j.numecd.2017.10.014]

135 **Li F**, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. *Sci China Life Sci* 2018; **61**: 770-778 [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9]

136 **Demir M**, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? *J Gastroenterol Hepatol* 2020; **35**: 1969-1977 [PMID: 32267559 DOI: 10.1111/jgh.15071]

137 **Monga Kravetz A**, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. *J Clin Endocrinol Metab* 2020; **105**: e3575-e3585 [PMID: 32561908 DOI: 10.1210/clinem/dgaa382]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 23, 2023

**First decision:** May 14, 2023

**Article in press:**

**Specialty type:** Microbiology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Perazzo JC, Argentina; Tovo CV, Brazil **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH


**Figure Legends**



**Figure 1 Gut microflora can affect several factors related to the development of metabolic-associated fatty liver disease.** These effects lead to the production of free fatty acids, insulin resistance, and impaired bile secretion in the liver, respectively. In addition, changes in intestinal microflora may lead to increased intestinal permeability, and microbial-derived compounds are transferred from the intestine to the liver through the portal vein, resulting in changes in pro-inflammatory signals, metabolism, and toxicity. Finally, ethanol and its toxic derivative acetaldehyde aggravated hyperoxidative stress and choline deficiency in hepatocytes. EtOH: Ethanol; LPS: Lipopolysaccharides; SCFAs: Short chain fatty acids; TNF-α: Tumor-necrosis factor.



**Figure 2 Mechanisms showing the role of gut microbiota in metabolic-associated fatty liver disease.** FXR: Farnesoid X receptor; TGR5: Takeda G protein-coupled; MAFLD: Metabolic-associated fatty liver disease; BA: Bile acid; LPS: Lipopolysaccharides; TNF-α: Tumor-necrosis factor alpha; TLR: Toll like receptor.



**Figure 3 Therapeutic interventions for metabolic-associated fatty liver disease based on microbiota.** Intestinal-centered therapy including antibiotics, bacterial metabolites, probiotics, engineered bacteria, bacteriophages, and fecal microbial transplantation can specifically interfere with intestinal microflora to re-establish the interface between the liver and the microbiome. MAFLD: Metabolic-associated fatty liver disease.

**Table 1 Studies presenting gut dysbiosis in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Subjects** | **Year** | **Alterations of GM (↑/↓)** | | | **Ref.** |
| **Phylum** | **Family** | **Genus/Species** |
| United States | Obese patients without NASH (*n* = 25), NASH (*n* = 22), Controls (*n* = 16) | 2013 | ↑*Bacteroidetes*; ↑*Proteobacteria*; ↓*Firmicutes*; ↓*Actinobacteria* | ↓*Bifidobacteriaceae*;↑*Alcaligenaceae*;↓*Clostridiales family XI*; ↑*Campylobacteraceae*;↓*Lachnospiraceae*; ↑*Enterobacteriaceae* | ↑*Prevotella*; ↑*Escherichia* | [69] |
| Canada | NAFLD (*n* = 33) *vs* Controls (*n* = 17) | 2013 | ↓*Bacteroidetes* | / | ↑*Clostridium* *coccoides* | [124] |
| Canada | NAFLD (*n* = 30) *vs* Controls (*n* = 30) | 2013 | ↑*Proteobacteria*;↑*Firmicutes*;↓*Bacteroidetes* | ↑*Kiloniellaceae*;↑*Pasteurellaceae*;↑*Lactobacillaceae*;↑*Lachnospiraceae*;↑*Veillonellaceae*;↓*Ruminococcaceae*;↓*Porphyromonadaceae* | ↑*Lactobacillu*;↑*Robinsoniella*;↑*Roseburia*;↑*Dorea*;↓*Oscillibacter* | [125] |
| Hong Kong | NASH (*n* = 16) *vs* Controls (*n* = 22) | 2013 | ↓*Firmicutes* | / | ↓*Faecalibacterium*;↓*Anaerosporobacter*;↑*Parabacteroides*;↑*Allisonella* | [126] |
| China | NAFLD (*n* = 53) *vs* Controls (*n* = 32) | 2015 | ↑*Firmicutes*;↑*Proteobacteria* | ↑*Peptostreptococcaceae*;↑*Lactobacillaceae*;↓*Ruminococcaceae*;↓*Porphyromonadaceae* | ↑*Escherichia*;↑*Lactobacillus*;↑*Streptococcus*;↑*Anaerobacter*;↓*Prevotella* | [127] |
| United States | Controls (*n* = 26), obese (*n* = 11), NAFLD (*n* = 13) | 2015 | ↑*Actinobacteria* | / | ↓*Erysipelotrichia*;↑*Prevotella*;↓*Alphaproteobacteria*;↑*Clostridia*;↓*Verrucomicrobia*;↑*Fusobacteria*;↑*Epsilonproteobacteria*;↑*Gammaproteobacteria* | [67] |
| France | NASH (*n* = 35) *vs* Controls (*n* = 22) | 2016 | ↑*Proteobacteria* | ↑*Enterobacteriaceae*;↓*Ruminococcaceae* | ↑*Ruminococcus*;↓*Prevotella*;↑*Escherichia*;↓*Anaerospacter*;↓*Coprococcus*;↓*Eubacterium*;↓*Faecalibacterium*;↑*Bacteroides* | [128] |
| Italy | NAFLD (*n* = 61) *vs* Controls (*n* = 54) | 2017 | ↑*Actinobacteria*;↓*Bacteroidetes* | ↓*Rikenellaceae* | ↑*Bradyrhizobium*;↑*Anaerococcus*;↑*Peptoniphilus*;↑*Ruminococcus*;↓*Oscillopira*;↑*Dorea*;↑*Blautia*;↑*Propionibacterium* *acnes* | [129] |
| China | NAFLD (*n* = 43) *vs* Controls (*n* = 83) | 2016 | ↑*Bacteroidetes*;↓*Firmicutes* | ↑*Bacteroidaceae*;↓*Lachnospiraceae*;↑*Prevotellaceae*;↓*Ruminococcaceae*;↓*Lactobacillaceae*;↓*Peptostreptococcaceae* | ↓*Coprococcus*;↓*Anaerosporobacter*;↓*Anaerotruncus*;↓*Ruminococcus*;↓*Lactobacillus* | [130] |
| China | NAFLD (*n* = 25) *vs* Controls (*n* = 22) | 2017 | ↑*Proteobacteria*;↓*Bacteroidetes* | ↑*Lachnospiraceae*;↑*Enterobacteriaceae*;↓*Prevotellaceae*;↓*Ruminococcaceae*;↑*Erysipelotrichaceae*;↑*Streptococcaceae* | ↑*Fusobacteria*;↓*Prevotella*;↑*Blautia*;↑*Escherichia*;↑*Shigella*;↑*Fusobacteria*;↑*Escherichia* *Shigella* | [131] |
| Canada | NAFLD (*n* = 39) *vs* Controls (*n* = 28) | 2018 | ↓*Firmicutes*; ↓*Bacteroidetes* | ↑*Lactobacillaceae* | ↓*Ruminococcus*;↓*Faecalibacterium*;↓*Coprococcus* | [132] |
| Italy | Obese, NAFL and NASH (*n* = 61) and Controls (*n* = 54) | 2016 | / | / | ↑*Lactobacilli*;↓*Bifidobacteria*;↑*Lactobacilli* *mucosae*;↓*Bifidobacteria* *longum*;↓*Bifidobacteria* *adolescent*;↓*Bifidobacteria* *bifidum* | [133] |
| Brazil | NASH (*n* = 13) *vs* Controls (*n* = 10) | 2017 | / | / | ↑*Bacteroides*;↑*Lactobacilli*;↓*Ruminococcu*;↓*Bifidobacterium*;↑*Prevotella*;↓*Faecalibacterium* | [134] |
| China | NAFLD (*n* = 30) *vs* Controls (*n* = 37) | 2018 | / | ↑*Lactobacillaceae*;↑*Veillonellaceae*;↑*Peptostreptococcaceae*;↑*Coprobacillaceae*;↑*Erysipelotrichaceae*;↓*Paraprevotellaceae*;↓*Victivallaceae* | ↑*Porphyromonas*; ↑*Clostridium*; ↑*Blautia*; ↑*Dorea*; ↑*Peptococcus*; ↑*Peptococcaceae\_rc4-4*; ↑*Mitsuokella*; ↑*Slackia*; ↑*Succinivibrio*; ↓*Odoribacter*; ↓*Coprococcus*; ↓*Proteus* | [135] |
| Germany | NAFLD (*n* = 90) *vs* Controls (*n* = 21) | 2020 | ↓*Bacteroidetes* | ↓*Ruminococcaceae*;↑*Lactobacillaceae*;↑*Veillonellaceae* | ↑*Dorea* | [136] |
| United States | NAFLD (*n* = 44) *vs* Controls (*n* = 29) | 2020 | ↓*Bacteroidetes* | / | ↓*Prevotella*;↓*Gemmiger*;↓*Oscillospira* | [137] |

NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis